🇮🇪Ireland
16°C Partly Cloudy · Dublin
Live Updates
--:--:-- IST
Contributor sign in
Latest
Clinical Trials in Egypt / NCT07579637
Active, not recruiting Not applicable

Effect of Vitamin D on Postoperative Pain in Symptomatic Irreversible Pulpitis

NCT07579637 · tracked via the Priya Life Science Egypt tracker
Phase
Not applicable
Started
2025-11-01
Last updated
2026-05-12

Condition(s) studied

Pulpitis - IrreversibleVitamin D Deficiency

Investigational drug(s) / intervention(s)

Vitamin D3Vitamin D3Placebo

Vitamin D3: Preoperative supplementation of 150000 IU Vitamin D3 soft gel oral capsules with dietary fat prior to single visit root canal treatment in mandibular first molar with symptomatic irreversible pulpitis

Vitamin D3: 50000 IU preoperative Vit D3 oral soft gel capsule with dietary fat prior to root canal treatment in mandibular first molars with symptomatic irreversible pulpitis followed by 50000 IU on the second day and 50000 IU on the third day.

Placebo: Matched soft Gel capsules to Vit D3 capsules, 3 oral soft gel capsules preoperative to single visit root canal treatment in mandibular first molars with symptomatic irreversible pulpitis

Study summary

Vitamin D deficiency (VDD) is a prevalent global health concern that has been linked to altered pain perception through its effects on inflammatory pathways, nociceptor activity, and neurotrophic signaling. While its role in chronic pain has been widely studied, limited evidence exists regarding its impact on acute postoperative dental pain. This triple-blinded randomized controlled clinical trial aims to evaluate the effect of moderate-dose vitamin D supplementation on postoperative pain following single-visit root canal treatment (RCT) in patients with symptomatic irreversible pulpitis affecting mandibular first molars. A total of 54 vitamin D-deficient patients (serum 25(OH)D \<30 nmol/L), aged 20-45 years, will be randomly allocated into three groups: a single preoperative dose group (150,000 IU vitamin D₃), a fractionated dose group (50,000 IU over three consecutive days), and a placebo group. All participants will undergo standardized single-visit RCT procedures. Postoperative pain will be assessed using a Modified Visual Analog Scale (VAS) at baseline and at 6, 12, 24, and 48 hours post-treatment, while analgesic intake will be recorded as a secondary outcome. It is hypothesized that vitamin D supplementation will significantly reduce postoperative pain levels and analgesic consumption compared to placebo. This study seeks to explore vitamin D as a safe, cost-effective adjunct in endodontic pain management, with potential implications for improving clinical outcomes in patients with VDD undergoing RCT.

Eligibility

Sex
ALL
Min age
20 Years
Max age
45 Years
Healthy volunteers
No
Inclusion Criteria: * Patients with serum 25-hydroxyvitamin D level below 30 nmol/L with no vitamin D supplementation for the preceding 3 months. * Patients diagnosed with symptomatic irreversible pulpitis. * Mandibular first molar: Classification of root canal configuration according to Weine's classification: * Distal root: with one portal of exit * Mesial root: Type III, two separate and distinct canals extend from the pulp chamber to the apex. * Patients with moderate to severe pre-operative pain with pain score from 6-10. * Medically free patients with no systemic disease: (American Society of Anesthesiologists / (ASA Class I or II). * The age range is between 20 to 45 years. * Patients have restorable mandibular permanent molars that were diagnosed with symptomatic irreversible pulpitis. * Positive patient's acceptance for participating in the study and signing informed consent Exclusion Criteria: * Patients that have been taking vitamin D supplements in the last 3 months. * Patients with serum 25-hydroxyvitamin D level above 30 nmol/L. * Patients diagnosed with necrosis, partial necrosis, acute or chronic abscess. * Presence of periapical radiolucency. * Patients with systemic conditions that may affect pain perception (e.g., fibromyalgia, diabetes, chronic pain disorders). * Pregnant or lactating females. * Psychologically disturbed patients. * Patients with a history of allergy to any medication used in the study are excluded. * Patients with mild to moderate pain with pain scores less than 6. * Teeth that have: * Periodontally affected molars with grade 2 or 3 mobility. * Non-restorable teeth. * Abnormal anatomy and calcified canals. * Previous root canal treatment. * Patients above 45 years old or below 20 years old. * Non-compliant patients to follow ups. * Patients with very poor oral hygiene.

Primary outcome measure(s)

Trial sites (1)

FacilityCityRegionStatus
Future University in Egypt New Cairo Select A State Or Province

More Future University in Egypt trials in Egypt

Other trials for the same condition

Official registry record

This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.

View NCT07579637 on ClinicalTrials.gov ↗ ← All trials in Egypt